Survey and Research Archives | Be Korea-savvy

Archive by category Survey and Research

Global Study on CEO Trends Indicates a Significant Uptick in CEOs Forced out of Office for Ethical Lapses: PwC’s Strategy&

Global Study on CEO Trends Indicates a Significant Uptick in CEOs Forced out of Office for Ethical Lapses: PwC’s Strategy&

LONDON, May 14 (Korea Bizwire) — The share of CEOs forced out of office for ethical lapses has been on the rise, according to the 2016 CEO Success study released today by Strategy&, PwC’s strategy consulting business. The study, which analyzed CEO successions at the world’s largest 2,500 public companies over the past 10 years, [...]

Abiomed Announces First Patient Enrolled in STEMI DTU Feasibility Study

Abiomed Announces First Patient Enrolled in STEMI DTU Feasibility Study

DANVERS, Mass., May 4 (Korea Bizwire) — Abiomed, Inc. (NASDAQ:ABMD), a leading provider of breakthrough heart support technologies, announced today the enrollment of the first patient in the Food and Drug Administration (FDA) approved prospective feasibility study, STEMI Door to Unloading (DTU) with Impella CP® system in acute myocardial infarction. This trial will focus on [...]

Dr. Oh Unveils Innovative ‘2Day LASEK’ Eye Surgery

Dr. Oh Unveils Innovative ‘2Day LASEK’ Eye Surgery

The following video contains the complete surgical procedure for 2day LASEK surgery. http://www.globenewswire.com/NewsRoom/AttachmentNg/49e30ba9-c3a0-4931-bfa9-ecb7ba63d676 SEOUL, Apr. 27 (Korea Bizwire) — We have reached an age when it takes only two days to restore wound healing following LASEK eye surgery. Dr. Oh Jung-woo of EOS Eye Clinic, a South Korean ophthalmologist, is unveiling the entire process of [...]

RedHill Biopharma Announces Enrollment of Last Patient in the BEKINDA® Phase II Study for IBS-D

RedHill Biopharma Announces Enrollment of Last Patient in the BEKINDA® Phase II Study for IBS-D

TEL-AVIV, Israel, Apr. 24 (Korea Bizwire) — RedHill Biopharma Ltd. (NASDAQ:RDHL) (Tel-Aviv Stock Exchange:RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on the development and commercialization of late clinical-stage, proprietary, orally-administered, small molecule drugs for gastrointestinal and inflammatory diseases and cancer, today announced enrollment of the last patient in the Phase II [...]

Botswana Most Attractive Investment Destination in Africa

Botswana Most Attractive Investment Destination in Africa

LONDON, Apr. 19 (Korea Bizwire) — Botswana is the most attractive economy for investments flowing into the African continent, according to the latest Africa Investment Index 2016 (http://APO.af/sUtRNQ) by Quantum Global’s (www.QuantumGlobalGroup.com) independent research arm, Quantum Global Research Lab. Multimedia content can be accessed here: http://APO.af/ZihCNl. According to the Index, Botswana, scores highly based on [...]

RedHill Biopharma Receives Notice of Allowance for Two Additional U.S. Patents Covering BEKINDA®

RedHill Biopharma Receives Notice of Allowance for Two Additional U.S. Patents Covering BEKINDA®

TEL-AVIV, Israel, Apr. 18 (Korea Bizwire) — RedHill Biopharma Ltd. (NASDAQ:RDHL) (Tel-Aviv Stock Exchange:RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on the development and commercialization of late clinical-stage, proprietary, orally-administered, small molecule drugs for gastrointestinal and inflammatory diseases and cancer, today announced that it has received notices of allowance from the [...]

New Study Published in PLOS ONE Advances Science Around VTS-270 for Treatment of Niemann-Pick Disease Type C1

New Study Published in PLOS ONE Advances Science Around VTS-270 for Treatment of Niemann-Pick Disease Type C1

ROCKVILLE, Md., Apr. 18 (Korea Bizwire) — Sucampo Pharmaceuticals, Inc. (Sucampo) (NASDAQ:SCMP), a global biopharmaceutical company, today announced the publication of a new study in an independent scientific journal that confirms the unique composition of VTS-270, a 2-Hydroxypropyl-beta-cyclodextrin (HPβCD) product under investigation as a novel treatment for Niemann-Pick Disease Type C1 (NPC-1). NPC-1 is a [...]

The Top Reason U.S. Consumers Unsubscribe from email is Because They Get Too Many emails in General, Cited by 26% of Consumers

The Top Reason U.S. Consumers Unsubscribe from email is Because They Get Too Many emails in General, Cited by 26% of Consumers

JACKSONVILLE, Fla., Apr. 4 (Korea Bizwire) – MarketingSherpa asked 1,200 U.S. consumers, “Why do you unsubscribe from the email lists of companies with which you are satisfied? Select all that apply,” and it asked another group of 1,200 the same question about companies with which they are unsatisfied. In previously released data, MarketingSherpa discovered that a satisfied customer is [...]